North America

By Richard Y. Cheung, Ph.D., Toronto, Fasken Martineau DuMoulin

Due to concerns about the growing percentage of the health care budget allotted to drug spending in Canada and the relative drug prices in Canada compared to other developed countries, the Canadian government is proposing changes to the way in which prices for patented drugs are regulated …

Read or download the full article below.

Tags: Canada, Life Sciences
Latest Updates
Related Articles
Related Articles by Jurisdiction
Righting a Wrong: Canadian Regulators Improve the Rights Offering Regime
Canadian regulatory authorities recently overhauled how prospectus exempt rights offerings are to be conducted going forward.
New Lobbyists’ Code Will Restrict Dealings with Canada’s Federal Government and Agencies
Canada's new Lobbyists' Code of Conduct will significantly restrict the activities of lobbyists and others seeking to influence federal decision making.
OSFI issues advisory on technology and cyber security incident reporting
The Advisory reflects the fact that OSFI is very focused on this increasingly significant area of risk.
Latest Articles